retatrutide nonalcoholic steatohepatitis trial Antifibrotic therapy in steatohepatitis: time for a human-centric approach Triple hormone receptor agonist retatrutide

But they are changing the landscape of medicine because they hit a fundamental biology we have ignored for too long: the gut-brain-metabolic axis

It is important to note that while there is an association between Zepbound use and gallbladder problems, the absolute risk remains relatively low

Regular office visits documenting your weight, BMI, blood pressure, and any obesity-related health conditions create the foundation for a strong prior authorization submission

doi: 10.1111/dom.12479 45 GiorginoFBenroubiMSunJHZimmermannAGPechtnerV

Despite these challenges, SMG 2.4 mg represents a breakthrough in the treatment of obesity and warrants further study of its long-term effects

doi:10.1001/jamaneurol.2025.2020 MSc